Celldex Therapeutics Inc. (Nasdaq: CLDX) announced upbeat results from two Phase 1 clinical studies of its cancer treatment CDX-1307 sending the stock price soaring $2.69 to $11.71.
Celldex Reports Upbeat Trial Results
June 01, 2009 at 14:11 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.